catridecacog at a glance
Medicine class
Recombinant coagulation factor XIII A-subunit replacement therapy.
How it is given
Injected into a vein after mixing the powder with its supplied solvent.
Specialist care
Treatment is initiated and supervised by a clinician experienced in rare bleeding disorders.
What is catridecacog used for?
UK-licensed uses are:
Long-term prevention of bleeding in adults and children with confirmed congenital factor XIII A-subunit deficiency.
Treatment of breakthrough bleeding during regular prophylaxis.
How does catridecacog work?
Factor XIII strengthens a new clot by cross-linking fibrin and other proteins. Catridecacog supplies the A-subunit, binds naturally occurring factor XIII B-subunits and, once activated, makes the clot stronger and more resistant to breakdown.
catridecacog preparations and strengths
Injection
Route: Parenteral
Strengths: 2500 units
How to take catridecacog
Catridecacog is injected into a vein following training from the specialist team.
Use aseptic technique when mixing the powder with the supplied solvent.
Gently swirl rather than shake.
The prepared solution should be clear and colourless; discard it if particles or discolouration are present.
Use the solution immediately after preparation and do not mix it with other medicines or infusion solutions.
Follow the injection method taught by the haemophilia team.
catridecacog side effects
Common or expected effects
- Headache
- Injection-site pain
- Pain in an arm or leg
- Reduced numbers of some white blood cells
- Increased fibrin D-dimer on blood testing
- Non-neutralising antibodies against factor XIII
Get urgent medical advice
- A severe allergic reaction, including anaphylaxis
- Symptoms of a blood clot or blocked blood vessel
- Unexpected bleeding or reduced treatment response, which may indicate an inhibitor
catridecacog in pregnancy
Evidence in pregnancy is limited, although available clinical experience has not identified harm to the pregnant woman, fetus or newborn. It may be considered only when clearly needed, with care coordinated by specialist bleeding-disorders and maternity teams.
catridecacog while breastfeeding
It is not known whether catridecacog passes into human milk. The prescriber should weigh the benefits of breastfeeding against the importance of treatment before deciding whether either should be interrupted.
catridecacog interactions
Clinical interaction data are limited. Tell the specialist team about all prescribed, over-the-counter and complementary products.
Recombinant activated factor VII (rFVIIa)
Combined use is not recommended because non-clinical evidence suggests an increased thrombotic effect.
Common questions about catridecacog
Answers are fully visible for fast scanning and source review.
What is catridecacog used for?
It prevents bleeding in people with congenital factor XIII A-subunit deficiency and can treat breakthrough bleeding during prophylaxis.
Does it treat factor XIII B-subunit deficiency?
No. Its long-term preventive effect is not reliable in congenital B-subunit deficiency.
Can it be used in children?
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.